Santhera to terminate Phase III DMD trial of Puldysa
Santhera will shift focus to DMD drug candidate vamorolone. Credit: Remaztered Studio from Pixabay.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more